Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL2354846 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL1728893 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL4920513 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL7537653 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL5679533 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL703430 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL509509 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL723498 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA | |
| Methylene Chloride SCHEMBL37333 | 1.00 | — | — | |
| Methylene Chloride SCHEMBL2350111 | 1.00 | TSHR (0.50) | TSHRTDP1TP53ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271369-A | Single/binuclear iridium complex with anti-saturation absorption capacity and preparation method and application thereof | 南京工业大学 | 2024-07-02 | — | — | CN | disclosed |
| EP-3345900-B1 | 2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | BEBETTER MED INC (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-20240182454-A1 | Polycyclic Compound for Inhibiting RNA Helicase DHX33, and Application of Compound | SHENZHEN KEYE LIFE TECHNOLOGIES, CO., LTD (CN) | 2024-06-06 | — | — | US | disclosed |
| EP-4378940-A1 | POLYCYCLIC COMPOUND FOR INHIBITING RNA HELICASE DHX33, AND APPLICATION OF COMPOUND | Shenzhen Keye Life Technologies, Co., Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024109684-A1 | USE OF 8-HYDROXYQUINOLINE DERIVATIVE | 江苏亚虹医药科技股份有限公司 | 2024-05-30 | — | — | WO | disclosed |
| CN-118063533-A | Modified nucleotide compound, oligonucleotide and application thereof | 广州必贝特医药股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118059101-A | Use of 8-hydroxyquinoline derivatives | 江苏亚虹医药科技股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-116615417-B | 1, 4-Diheterocyclic group substituted aromatic ring or aromatic heterocyclic compound and application thereof | 广州必贝特医药股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4349815-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2024-04-10 | — | — | EP | disclosed |
| CN-116003406-B | Heteroaryl ring nitroxide compound and preparation method and application thereof | 北京鞍石生物科技有限责任公司 | 2024-01-23 | — | — | CN | disclosed |
| US-8415370-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-04-09 | — | — | US | disclosed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | disclosed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2099814-A1 | SUBSTITUTED ESTRATRIEN DERIVATIVES AS 17BETA HSD INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2009-09-16 | — | — | EP | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008065100-A1 | SUBSTITUTED ESTRATRIEN DERIVATIVES AS 17BETA HSD INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-06-05 | — | — | WO | disclosed |
| US-4963566-A | ANTIULCER AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | TSHR 3412/4885TDP1 446/4885TP53 58/4885 |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV3, TRPC3, TRPV1 | TSHR 2636/4885TDP1 2519/4885TP53 2422/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | TSHR 2605/4885TDP1 2499/4885TP53 2274/4885 |
| US-20240182454-A1 | Polycyclic Compound for Inhibiting RNA Helicase DHX33, and Application of Compound | DHX36, DDX3X, DDX21 | TSHR 4701/4885TDP1 626/4885TP53 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.